Sepsis Clinical Trial
— COMMITOfficial title:
Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis
NCT number | NCT01484106 |
Other study ID # | 01-CM-2011 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2011 |
Est. completion date | August 2014 |
Verified date | July 2021 |
Source | Baxter Healthcare Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to test whether a fluid resuscitation protocol guided by non-invasive hemodynamic measures reduces the progression of organ dysfunction (defined by an increase in the Serial Organ Failure Assessment Score ≥ 1 over the first 72 hours) in sepsis patients presenting to the Emergency Department without evidence of shock.
Status | Completed |
Enrollment | 65 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult patients > 18 years with old suspected or confirmed infection 2. At least two of the following four criteria (SIRS): 1. Temperature > 38 or < 36o C 2. Heart rate > 90 bpm 3. Respiratory rate > 20 bpm or PaCO2< 32 mmHg 4. White blood cell count >12,000 or <4,000 per mm3; or >10% bandemia 3. Lactate =2.0 and =4.0 mMol/L 4. Enrollment within 6 hours of ED presentation within 2.5 hours of meeting eligibility criteria Exclusion Criteria: 1. Age < 18 years 2. On vasopressor therapy 3. Systolic blood pressure < 90 mmHg 4. Received more than 3-liter crystalloid fluid prior to randomization 5. Patient presenting with pulmonary edema 6. Patient presenting with acute coronary syndrome 7. Patient presenting with new onset cardiac arrhythmia 8. Patient presenting with trauma, including burns 9. Patient requires immediate surgery 10. Patient presenting with stroke 11. Patient with end stage renal disease on renal replacement therapy 12. Patient with known pregnancy 13. Patient being treated with immunosuppressive therapy for organ transplant |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama | Birmingham | Alabama |
United States | Dr. Nate Shapiro | Boston | Massachusetts |
United States | MGH | Boston | Massachusetts |
United States | The Brigham and Women's Hospital | Boston | Massachusetts |
United States | NY Methodist Hospital | Brooklyn | New York |
United States | Denver Health and Hospital Authority | Denver | Colorado |
United States | Northwester University | Evanston | Illinois |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Sentara Norfolk General Hospital | Norfolk | Virginia |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | University of California | Sacramento | California |
United States | Humility of Mary Health Partners | Youngstown | Ohio |
Lead Sponsor | Collaborator |
---|---|
Cheetah Medical Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | sequential organ failure assessment score increases by greater or equal to 1 point from the baseline score within 72 hours of study enrollment. | A patient will be considered to have progressive organ dysfunction if their "Sequential Organ Failure Assessment" (SOFA) score increases by =1 point from their baseline score within 72 hours of study enrollment. | 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |